Retatrutide: Maintained at established dose (typically 8 to 12 mg weekly) BPC-157: 0.25 mg daily TB-500: 2.5 mg twice weekly (loading) or 2 mg weekly (maintenance) GHK-Cu: 0.1 to 0.2 mg three times weekly Duration: 8 to 12 weeks maximum, with 30-day minimum break between cycles The injection schedule for the complete GLOW protocol requires careful organization
BPC-157 Peptide Synthesized and Lyophilized in Canada by Koi Peptides Domestic Synthesis at a Canadian Facility The 15-residue chain comes together at Koi's Canadian production partner through standard Fmoc solid-phase chemistry, with the unusually high proline content (four prolines, including the Pro-Pro-Pro stretch at positions 3 to 5) handled through coupling protocols tuned for sterically hindered residues
Stuart A Montgomery 1, L J Thal, R Amrein Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimers disease National Library of Medicine, 2003 Mar;18(2):61-71
Supplementary Table 2 (download XLSX Metabolism focused CRISPR genetic screens in SLC25A39 -knockout Jurkat and HEK 293T cells
Browse our full Certificates of Analysis archive and learn about our Quality & Testing process
Myself and a couple of my friends all had a great experience with synergy and highly recommend it